PHASE II: DOXIL CYCLOPHOSPHAMIDE,VINCRISTINE & PREDNISONE:AIDS SYSTEMIC LYMPHOMA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。使用脂质体包裹的药物治疗是一种相对较新的药物输送方式，它似乎可以提高用于治疗癌症的药物的疗效和耐受性。Doxil是一种通过这种方式给药的阿霉素制剂。本研究比较了多西环素与常规阿霉素为主的化疗方案对艾滋病相关性系统性淋巴瘤患者的疗效和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Drug therapy using liposomal encapsulation is a relatively new way of drug delivery that appears to enhance efficacy and tolerability of medications used to treat cancer. Doxil is a Doxorubicin formulation delivered this way. This study compares the efficacy and tolerability of Doxil in patients with Aids related systemic lymphoma with conventional doxorubicin-based chemotherapy.